Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1987 Nov;25(3):245–249. doi: 10.1007/BF00199154

Enhancement of interleukin-2 release in rats by treatment with bleomycin and Adriamycin in vivo

Tarek A Abdul Hamied 1,✉, John L Turk 1
PMCID: PMC11038167  PMID: 2445487

Abstract

Spleen cells from rats previously injected with bleomycin (10 mg/kg) or Adriamycin (1 mg/kg) were able to release higher levels of interleukin-2 (IL-2) than cells from untreated animals. The difference in IL-2 release was detected after the cells were exposed to a suboptimal dose of concanavalin A (0.5 μg/ml) for 24 h. By cytofluorimetry, these drugs did not change the proportion of W3/25+ (helper) or OX-8+ (suppressor) T-cell subsets. In contrast, the immunosuppressive drug cyclophosphamide inhibited the IL-2 release from spleen cells under the same conditions. It is suggested that some anti-cancer antibiotics may be able to enhance the release of IL-2 while other cytotoxic drugs with more immunosuppressive potential could inhibit the release of this mediator.

Keywords: Cancer Research, Cyclophosphamide, Bleomycin, Adriamycin, Spleen Cell

References

  • 1.Abdul Hamied TA, Parker D, Turk JL. Potentiation of the release of interleukin-2 by bleomycin. Immunopharmacology. 1986;12:127. doi: 10.1016/0162-3109(86)90038-x. [DOI] [PubMed] [Google Scholar]
  • 2.Abdul Hamied TA, Parker D, Turk JL (1987) Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTAZ (INN mafosfamide) on the release of IL-2 and IL-1 in vitro. Int J Immunopharmacol (in press) [DOI] [PubMed]
  • 3.Brideau RJ, Carter PB, McMaster R, Mason DW, Williams AF. Two subsets of rat T-lymphocytes defined with monoclonal antibodies. Eur J Immunol. 1980;10:609. doi: 10.1002/eji.1830100807. [DOI] [PubMed] [Google Scholar]
  • 4.Cohen S, Salazar D, Wicher J. Adriamycin-induced activation of NK activity may initially involve LAF production. Cancer Immunol Immunother. 1983;15:188. doi: 10.1007/BF00199163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ehrke MJ, Cohen SA, Mihich E. Selective effects of adriamycin on murine host defence systems. Immunol Ref. 1982;65:55. doi: 10.1111/j.1600-065x.1982.tb00427.x. [DOI] [PubMed] [Google Scholar]
  • 6.Exon JH, Talcott PA, Koller LD. Effect of lead, polychlorinated biphenyls and cyclophosphamide on rat natural killer cells, interleukin-2 and antibody synthesis. Fundam Appl Toxicol. 1985;5:158. doi: 10.1016/0272-0590(85)90060-0. [DOI] [PubMed] [Google Scholar]
  • 7.Exon JH, Henningson GM, Koller LD, Talcotte PA. The selectivity of isoprinosine, NPT 15392, avridine and cyclophosphamide on multiple immune responses in rats. Int J Immunopharmacol. 1986;8:53. doi: 10.1016/0192-0561(86)90073-1. [DOI] [PubMed] [Google Scholar]
  • 8.Gillis S, Ferm MM, Ou W, Smith KA. T-cell growth factor: Parameters of production and a quantitative microassay for activity. J Immunol. 1978;120:2027. [PubMed] [Google Scholar]
  • 9.Hancock EJ, Kilburn DG. The effects of cyclophosphamide on in vitro cytotoxic responses to syngeneic tumour. Cancer Immunol Immunother. 1982;14:54. doi: 10.1007/BF00199433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hudson L, Hay FC. Immunofluorescent staining of lymphocyte membranes. In: Hudson L, Hay FC, editors. Practical immunology. London: Blackwell Scientific Publishers; 1976. pp. 34–35. [Google Scholar]
  • 11.Merluzzi VJ, Kenney RE, Schmid FA, Choi YY, Faanes RB. Recovery of the in vitro cytotoxic T-cell response in cyclophosphamide treated mice by injection of mixed lymphocyte culture supernatants. Cancer Res. 1981;41:3663. [PubMed] [Google Scholar]
  • 12.Morikawa K, Hosokawa M, Hamada J, Sugawara M, Kobayashi H. Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma. Cancer Res. 1985;45:1502. [PubMed] [Google Scholar]
  • 13.Ozer H. Effects of alkylating agents on immunoregulatory mechanisms. In: Mihich E, Sakurai S, editors. Biological responses in cancer vol 3, immunomodulation by anticancer drugs. New York: Plenum Press; 1985. pp. 95–130. [Google Scholar]
  • 14.Parker D, Turk JL. Potentiation of T-lymphocyte function of bleomycin. Immunopharmacology. 1984;7:109. doi: 10.1016/0162-3109(84)90060-2. [DOI] [PubMed] [Google Scholar]
  • 15.Tan BTG, Ekelaar F, Luirink J, Rimmelzwaan G, De Jonge AJR, Scheper RJ. Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia like antigen. The value of immunohistochemical screening. Hybridoma. 1985;4:155. doi: 10.1089/hyb.1985.4.115. [DOI] [PubMed] [Google Scholar]
  • 16.Turk JL, Parker D. Effect of cyclophosphamide on the immunological control mechanisms. Immunol Rev. 1982;65:99. doi: 10.1111/j.1600-065x.1982.tb00429.x. [DOI] [PubMed] [Google Scholar]
  • 17.White RAH, Mason DW, Williams AF, Galfre G, Milstein C. T-lymphocyte heterogeneity in the rat: separation of functional subpopulations using a monoclonal antibody. J Exp Med. 1978;148:664. doi: 10.1084/jem.148.3.664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Williams AF, Galfre G, Milstein C. Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: Differentiation antigens of rat lymphocytes. Cell. 1977;12:663. doi: 10.1016/0092-8674(77)90266-5. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES